BlueRock Therapeutics

New Capabilities

As of May 2026: Reported positive 36-month Phase I results; received Japan SAKIGAKE designation; enrolling patients in Phase III pivotal trial exPDite-2

For more than 50 years, Parkinson's disease treatment has meant managing symptoms with medication—not addressing the root cause: the death of dopamine-producing brain cells. Now, clinical trials are testing whether stem cell therapies can actually replace those lost neurons.

Updated May 27